JP2008528467A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528467A5 JP2008528467A5 JP2007551742A JP2007551742A JP2008528467A5 JP 2008528467 A5 JP2008528467 A5 JP 2008528467A5 JP 2007551742 A JP2007551742 A JP 2007551742A JP 2007551742 A JP2007551742 A JP 2007551742A JP 2008528467 A5 JP2008528467 A5 JP 2008528467A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- cancer
- compound
- fluorine
- hydrocarbyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- -1 2,6-dichlorophenyl Chemical group 0.000 claims 14
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 9
- 229910052731 fluorine Inorganic materials 0.000 claims 9
- 239000011737 fluorine Substances 0.000 claims 9
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 7
- 229910052801 chlorine Inorganic materials 0.000 claims 7
- 239000000460 chlorine Substances 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 125000002837 carbocyclic group Chemical group 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- YPSOVQYHIDHKDO-UHFFFAOYSA-N tert-butyl 4-[[4-[(2,6-dichlorobenzoyl)amino]-1h-pyrazole-5-carbonyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC(=O)C1=NNC=C1NC(=O)C1=C(Cl)C=CC=C1Cl YPSOVQYHIDHKDO-UHFFFAOYSA-N 0.000 claims 2
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 108091007914 CDKs Proteins 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims 1
- WIFZVEQCDXYJTR-UHFFFAOYSA-N ethenyl 4-[[4-[(2,6-dichlorobenzoyl)amino]-1h-pyrazole-5-carbonyl]amino]piperidine-1-carboxylate Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCN(C(=O)OC=C)CC1 WIFZVEQCDXYJTR-UHFFFAOYSA-N 0.000 claims 1
- KSUTVVOXLOPRBX-UHFFFAOYSA-N ethyl 4-[[4-[(2,6-dichlorobenzoyl)amino]-1h-pyrazole-5-carbonyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC(=O)C1=NNC=C1NC(=O)C1=C(Cl)C=CC=C1Cl KSUTVVOXLOPRBX-UHFFFAOYSA-N 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 claims 1
- XMSZANIMCDLNKA-UHFFFAOYSA-N methyl hypofluorite Chemical group COF XMSZANIMCDLNKA-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- KZUNCMJJRARVTM-UHFFFAOYSA-N propan-2-yl 4-[[4-[(2,6-dichlorobenzoyl)amino]-1h-pyrazole-5-carbonyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1NC(=O)C1=NNC=C1NC(=O)C1=C(Cl)C=CC=C1Cl KZUNCMJJRARVTM-UHFFFAOYSA-N 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 208000001608 teratocarcinoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64621705P | 2005-01-21 | 2005-01-21 | |
| GB0501480A GB0501480D0 (en) | 2005-01-22 | 2005-01-22 | Pharmaceutical compounds |
| GB0501748A GB0501748D0 (en) | 2005-01-27 | 2005-01-27 | Pharmaceutical compounds |
| US65133905P | 2005-02-09 | 2005-02-09 | |
| PCT/GB2006/000196 WO2006077419A1 (en) | 2005-01-21 | 2006-01-20 | Pyrazole derivatives for the inhibition of cdk' s and gsk' s |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008528467A JP2008528467A (ja) | 2008-07-31 |
| JP2008528467A5 true JP2008528467A5 (enExample) | 2009-03-19 |
Family
ID=35967182
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007551740A Withdrawn JP2008528466A (ja) | 2005-01-21 | 2006-01-20 | Ｃｄｋおよびｇｓｋ阻害ピラゾール誘導体 |
| JP2007551742A Pending JP2008528467A (ja) | 2005-01-21 | 2006-01-20 | Ｃｄｋおよびｇｓｋの阻害のためのピラゾール誘導体 |
| JP2007551739A Pending JP2008528465A (ja) | 2005-01-21 | 2006-01-20 | Ｃｄｋおよびｇｓｋの阻害のためのピラゾール誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007551740A Withdrawn JP2008528466A (ja) | 2005-01-21 | 2006-01-20 | Ｃｄｋおよびｇｓｋ阻害ピラゾール誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007551739A Pending JP2008528465A (ja) | 2005-01-21 | 2006-01-20 | Ｃｄｋおよびｇｓｋの阻害のためのピラゾール誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20080194562A1 (enExample) |
| EP (3) | EP1853600A1 (enExample) |
| JP (3) | JP2008528466A (enExample) |
| KR (3) | KR20070098927A (enExample) |
| AR (3) | AR052559A1 (enExample) |
| AU (3) | AU2006207311A1 (enExample) |
| BR (2) | BRPI0606317A2 (enExample) |
| CA (3) | CA2593656A1 (enExample) |
| IL (3) | IL184499A0 (enExample) |
| MA (3) | MA29253B1 (enExample) |
| MX (3) | MX2007008784A (enExample) |
| NO (3) | NO20073960L (enExample) |
| PE (3) | PE20060876A1 (enExample) |
| TN (3) | TNSN07279A1 (enExample) |
| WO (3) | WO2006077419A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005012256A1 (en) * | 2003-07-22 | 2005-02-10 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| TW200533657A (en) | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| US20080161251A1 (en) * | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Pharmaceutical Compounds |
| AR054425A1 (es) * | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| US20080161355A1 (en) * | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents |
| CA2594477C (en) * | 2005-01-21 | 2016-07-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
| AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| US20080139620A1 (en) * | 2005-01-21 | 2008-06-12 | Astex Therapeutics Limited | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's |
| WO2006093271A1 (ja) * | 2005-03-03 | 2006-09-08 | Mitsubishi Rayon Co., Ltd. | ポリマー粒子、これを含む樹脂組成物、成形体 |
| US7897589B2 (en) | 2005-07-15 | 2011-03-01 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
| EP1743892A1 (en) | 2005-07-15 | 2007-01-17 | Laboratorios del Dr. Esteve S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
| EP1743890A1 (en) | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments |
| EP2027109A1 (en) * | 2006-05-05 | 2009-02-25 | Astex Therapeutics Limited | 4- (2, 6-dichloro-benzoylamino) -1h-pyrazole-s-carboxylic acid (1-methanesulph0nyl-piperidin-4-yl) -amide for the treatment of cancer |
| JP2009536186A (ja) * | 2006-05-08 | 2009-10-08 | アステックス・セラピューティクス・リミテッド | 癌処置のためのジアゾール誘導体の医薬組合せ |
| US20100021420A1 (en) * | 2006-07-14 | 2010-01-28 | Astex Therapeutics Limited | Combinations of pyrazole derivatives for the inhibition of cdks and gsk's |
| EP2049516A2 (en) * | 2006-07-14 | 2009-04-22 | Astex Therapeutics Limited | Pharmaceutical compounds |
| US20090318430A1 (en) * | 2006-07-21 | 2009-12-24 | Astex Therapeutics Limited | Medical use of cyclin dependent kinases inhibitors |
| WO2008023720A1 (en) * | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | Urea compound or salt thereof |
| WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| MX2009004861A (es) * | 2006-11-09 | 2009-05-21 | Abbott Gmbh & Co Kg | Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa. |
| FR2908409B1 (fr) * | 2006-11-10 | 2009-01-09 | Sanofi Aventis Sa | Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation |
| FR2913018A1 (fr) * | 2007-02-23 | 2008-08-29 | Sanofi Aventis Sa | Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs |
| EP2267459A1 (en) * | 2009-06-25 | 2010-12-29 | Universite Pierre Et Marie Curie - Paris VI | Method for determining the susceptibility of a cell strain to drugs |
| CA2834049C (en) | 2011-04-25 | 2018-05-22 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| DE102011106990B3 (de) * | 2011-07-08 | 2013-01-03 | Technische Universität Darmstadt | Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen |
| BRPI1107312B1 (pt) | 2011-11-25 | 2021-09-08 | Universidade Federal De Santa Catarina | Composto de acil-hidrazona |
| AU2013224302B2 (en) * | 2012-02-21 | 2017-03-30 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| EP3173788A3 (en) * | 2012-03-14 | 2017-07-12 | Marx, Stephen | Means and methods for diagnostics and therapeutics of diseases |
| JP6290910B2 (ja) * | 2012-10-25 | 2018-03-07 | アッシャー・サード・イニシアティブ・インコーポレイテッド | ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法 |
| US8765762B2 (en) | 2012-10-25 | 2014-07-01 | Usher III, Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome |
| US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| EP2935249B1 (en) | 2012-12-19 | 2018-12-12 | Novartis AG | Autotaxin inhibitors |
| US9409895B2 (en) | 2012-12-19 | 2016-08-09 | Novartis Ag | Autotaxin inhibitors |
| ES2768651T3 (es) | 2013-04-25 | 2020-06-23 | Kyorin Seiyaku Kk | Composición farmacéutica sólida |
| WO2014179144A1 (en) * | 2013-04-29 | 2014-11-06 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
| EP2980088A1 (en) | 2014-07-28 | 2016-02-03 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| WO2015113927A1 (en) * | 2014-01-29 | 2015-08-06 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| EP3193606B1 (en) | 2014-09-10 | 2020-06-24 | Epizyme, Inc. | Isoxazole carboxamides as irreversible smyd inhibitors |
| AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| TWI730959B (zh) | 2015-05-19 | 2021-06-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| US12107225B2 (en) | 2018-03-27 | 2024-10-01 | Daikin Industries, Ltd. | Electrolyte solution, electrochemical device, lithium ion secondary battery, module and compound |
| EP3764451B1 (en) | 2018-03-27 | 2022-10-12 | Daikin Industries, Ltd. | Electrolyte solution, electrochemical device, lithium-ion secondary battery, and module |
| JP6954456B2 (ja) | 2018-03-27 | 2021-10-27 | ダイキン工業株式会社 | スルファミン酸リチウムの製造方法及び新規スルファミン酸リチウム |
| JP7590185B2 (ja) * | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
| WO2020140098A1 (en) | 2018-12-28 | 2020-07-02 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| CN111848579B (zh) * | 2019-04-26 | 2023-11-14 | 君实润佳(上海)医药科技有限公司 | 4-(2,6-二氯苯甲酰氨基)-n-(4-哌啶基)-1h-吡唑-3-甲酰胺的前药 |
| WO2022011091A1 (en) | 2020-07-09 | 2022-01-13 | Usher Iii Initiative, Inc. | Treatment of cancer, inflammatory diseases and autoimmune diseases |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| TW202320750A (zh) * | 2021-10-25 | 2023-06-01 | 香港商優領醫藥科技(香港)有限公司 | 含四氫呋喃多環類衍生物、其藥學上可接受的鹽及其製備方法和應用 |
| TW202337434A (zh) * | 2022-02-11 | 2023-10-01 | 美商傳達治療有限公司 | Ｃｄｋ抑制劑及其使用方法 |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4282361A (en) * | 1978-03-16 | 1981-08-04 | Massachusetts Institute Of Technology | Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines |
| US5502068A (en) * | 1995-01-31 | 1996-03-26 | Synphar Laboratories, Inc. | Cyclopropylpyrroloindole-oligopeptide anticancer agents |
| AU703203B2 (en) * | 1996-01-30 | 1999-03-18 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| AU2001241128A1 (en) * | 2000-03-14 | 2001-09-24 | Fujisawa Pharmaceutical Co. Ltd. | Novel amide compounds |
| US6455559B1 (en) * | 2001-07-19 | 2002-09-24 | Pharmacia Italia S.P.A. | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| JPWO2002074298A1 (ja) * | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
| GB0218625D0 (en) * | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| US7169797B2 (en) * | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
| US7320989B2 (en) * | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
| TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| WO2005012256A1 (en) * | 2003-07-22 | 2005-02-10 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| US20080161355A1 (en) * | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents |
| AR054425A1 (es) * | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| CA2594477C (en) * | 2005-01-21 | 2016-07-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
| US20080139620A1 (en) * | 2005-01-21 | 2008-06-12 | Astex Therapeutics Limited | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's |
| US20080161251A1 (en) * | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Pharmaceutical Compounds |
| AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
-
2006
- 2006-01-19 AR ARP060100204A patent/AR052559A1/es not_active Application Discontinuation
- 2006-01-19 AR ARP060100202A patent/AR053662A1/es not_active Application Discontinuation
- 2006-01-19 AR ARP060100205A patent/AR052660A1/es not_active Application Discontinuation
- 2006-01-20 MX MX2007008784A patent/MX2007008784A/es not_active Application Discontinuation
- 2006-01-20 MX MX2007008782A patent/MX2007008782A/es not_active Application Discontinuation
- 2006-01-20 EP EP06700940A patent/EP1853600A1/en not_active Withdrawn
- 2006-01-20 WO PCT/GB2006/000196 patent/WO2006077419A1/en not_active Ceased
- 2006-01-20 KR KR1020077018916A patent/KR20070098927A/ko not_active Withdrawn
- 2006-01-20 BR BRPI0606317-9A patent/BRPI0606317A2/pt not_active IP Right Cessation
- 2006-01-20 JP JP2007551740A patent/JP2008528466A/ja not_active Withdrawn
- 2006-01-20 PE PE2006000079A patent/PE20060876A1/es not_active Application Discontinuation
- 2006-01-20 AU AU2006207311A patent/AU2006207311A1/en not_active Abandoned
- 2006-01-20 US US11/814,446 patent/US20080194562A1/en not_active Abandoned
- 2006-01-20 BR BRPI0606107-9A patent/BRPI0606107A2/pt not_active IP Right Cessation
- 2006-01-20 CA CA002593656A patent/CA2593656A1/en not_active Abandoned
- 2006-01-20 CA CA002593468A patent/CA2593468A1/en not_active Abandoned
- 2006-01-20 US US11/814,443 patent/US20080306069A1/en not_active Abandoned
- 2006-01-20 JP JP2007551742A patent/JP2008528467A/ja active Pending
- 2006-01-20 WO PCT/GB2006/000191 patent/WO2006077414A1/en not_active Ceased
- 2006-01-20 KR KR1020077018917A patent/KR20070098928A/ko not_active Withdrawn
- 2006-01-20 WO PCT/GB2006/000193 patent/WO2006077416A1/en not_active Ceased
- 2006-01-20 EP EP06704677A patent/EP1853584A1/en not_active Withdrawn
- 2006-01-20 EP EP06709562A patent/EP1846395A1/en not_active Withdrawn
- 2006-01-20 PE PE2006000081A patent/PE20061198A1/es not_active Application Discontinuation
- 2006-01-20 KR KR1020077018915A patent/KR20070107049A/ko not_active Withdrawn
- 2006-01-20 AU AU2006207313A patent/AU2006207313A1/en not_active Abandoned
- 2006-01-20 CA CA002593465A patent/CA2593465A1/en not_active Abandoned
- 2006-01-20 MX MX2007008780A patent/MX2007008780A/es not_active Application Discontinuation
- 2006-01-20 JP JP2007551739A patent/JP2008528465A/ja active Pending
- 2006-01-20 PE PE2006000080A patent/PE20061073A1/es not_active Application Discontinuation
- 2006-01-20 AU AU2006207316A patent/AU2006207316A1/en not_active Abandoned
-
2007
- 2007-07-09 IL IL184499A patent/IL184499A0/en unknown
- 2007-07-09 IL IL184502A patent/IL184502A0/en unknown
- 2007-07-09 IL IL184503A patent/IL184503A0/en unknown
- 2007-07-20 TN TNP2007000279A patent/TNSN07279A1/en unknown
- 2007-07-20 TN TNP2007000278A patent/TNSN07278A1/en unknown
- 2007-07-20 TN TNP2007000281A patent/TNSN07281A1/en unknown
- 2007-07-27 NO NO20073960A patent/NO20073960L/no not_active Application Discontinuation
- 2007-07-27 NO NO20073956A patent/NO20073956L/no not_active Application Discontinuation
- 2007-07-27 NO NO20073955A patent/NO20073955L/no not_active Application Discontinuation
- 2007-08-16 MA MA30143A patent/MA29253B1/fr unknown
- 2007-08-16 MA MA30145A patent/MA29255B1/fr unknown
- 2007-08-16 MA MA30144A patent/MA29254B1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6013375B2 (ja) | キナーゼ阻害剤としてのチアゾリルフェニル−ベンゼンスルホンアミド誘導体 | |
| KR101964251B1 (ko) | 약학적 화합물 | |
| JP2008528465A5 (enExample) | ||
| JP2020503299A5 (enExample) | ||
| JP2009543771A5 (enExample) | ||
| CA2939164A1 (en) | Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use | |
| JP2014506599A5 (enExample) | ||
| JP2008538750A5 (enExample) | ||
| US20210261542A1 (en) | Compounds which inhibit rna polymerase, compositions including such compounds, and their use | |
| JP2011506402A5 (enExample) | ||
| JP2025521091A5 (enExample) | ||
| JP2008505167A5 (enExample) | ||
| CA2771775A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| JP6380777B2 (ja) | ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物 | |
| JP2011516536A5 (enExample) | ||
| JP2005508953A5 (enExample) | ||
| JP2011513419A5 (enExample) | ||
| JP2022539208A (ja) | チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用 | |
| JP2008506761A5 (enExample) | ||
| WO2022170164A1 (en) | Sulfonamides with egfr inhibition activities and their use thereof | |
| JP2009537606A5 (enExample) | ||
| RU2008127264A (ru) | Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза | |
| KR102682516B1 (ko) | 퀴놀린 구조를 갖는 pan-kit 키나제 억제제 및 이의 용도 | |
| RU2007144522A (ru) | Производные пиримидиламинобензамида для лечения синдрома гиперэозинофилии | |
| RU2007131103A (ru) | Производные пиразола, предназначенные для ингибирования циклинзависимых киназ (cdk) и киназ гликогенсинтазы (gsk) |